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Abstract: Type I collagen, the predominant protein of vertebrates, assembles into fibrils that orchestrate the form and function of bone, tendon, skin, and other tissues. Collagen plays roles in
hemostasis, wound healing, angiogenesis, and biomineralization, and its dysfunction contributes to
fibrosis, atherosclerosis, cancer metastasis, and brittle bone disease. To elucidate the type I collagen
structure-function relationship, we constructed a type I collagen fibril interactome, including its
functional sites and disease-associated mutations. When projected onto an X-ray diffraction model of
the native collagen microfibril, data revealed a matrix interaction domain that assumes structural
roles including collagen assembly, crosslinking, proteoglycan (PG) binding, and mineralization, and
the cell interaction domain supporting dynamic aspects of collagen biology such as hemostasis,
tissue remodeling, and cell adhesion. Our type III collagen interactome corroborates this model. We
propose that in quiescent tissues, the fibril projects a structural face; however, tissue injury releases
blood into the collagenous stroma, triggering exposure of the fibrils’ cell and ligand binding sites
crucial for tissue remodeling and regeneration. Applications of our research include discovery of
anti-fibrotic antibodies and elucidating their interactions with collagen, and using insights from our
angiogenesis studies and collagen structure-function model to inform the design of super-angiogenic
collagens and collagen mimetics.
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1. Introduction
Collagens are among the most ubiquitous and complex of the vertebrate extracellular matrix (ECM) macromolecules [1–5]. About thirty genetically distinct collagens are
expressed in human connective tissues. For most, the majority of their sequences exist as
triple helices, which makes them unique among proteins. Triple helices are rigid, rope-like
protein conformations which, depending on the collagen type, may be interspersed between small flexible non-triple helical regions, or larger, globular non-collagenous regions.
The triple helical regions are composed of contiguous Gly-X-Y tripeptide repeats, with Gly
residues being supported at this position because they are small enough to fit the confines
of the three peptide chains that form the triple helix. The extent of the triple helical region,
along with the presence of non-triple helical regions, determines the type of aggregate
collagen molecules make, and how they contribute to the intricate ECM scaffold that makes
up the internal architecture of the vertebrate body.
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Type I collagen is the prototypical collagen that aggregates into fibrils. It is the
most abundant protein in the human body, comprising about 7 kg of the dry weight of
the human adult. There are approximately 1 × 1023 collagen molecules in the human
body [6]. Remarkably, if the collagen molecules from an adult human were laid end to
end, the resulting rope would be long enough to lasso the Moon from the Earth many
times over, or easily span the distance between the Earth and the Sun [7]. That so many
collagen molecules are packed tightly within one organism is a testament to the exquisite
and efficient way vertebrate cells assemble and twist collagen molecules into rope-like
fibrils—the most abundant molecular aggregate formed by collagens in vivo.
Type I collagen comprises much of the substance of connective tissues including
tendon, ligaments and skin, and most of the organic phase of bone, and supports and
provides form to many other tissues of the vertebrate body via the connective tissue
proper [1,3,8]. In bone, the type I collagen fibril also serves as the site for mineralization
either directly, or by its association with mineralization nucleation proteins [9–12]. It is
therefore no surprise that type I collagen plays crucial roles in vital physiologic processes,
including hemostasis, angiogenesis, and biomineralization, and in human pathologies
including cancer, fibrosis, and atherosclerosis [3,13,14]. Type I collagen from animal sources
is also the most widely used biomaterial for fabrication of bone regeneration scaffolds,
hemostats, bandages, and tendon repair patches [15]. Therefore, from both the basic
and applied standpoints, it is of paramount interest to understand collagen biology and
define the collagen structure-function relationship. Here we will review our research on
creating and analyzing type I collagen and type III collagen interactomes, and our use
of computational approaches to model these collagens’ molecular interactions with cells,
bioactive factors, and other macromolecules. Further, we will discuss how our findings
inform applications including the design and discovery of anti-fibrotic and pro-angiogenic
therapies.
2. Type I Collagen Structure and Assembly
Type I collagen is synthesized by cells as pro-α1 and pro-α2 procollagen chains,
encoded by separate genes and comprising about 1000 amino acid residues each [2].
The C-terminal propeptides promote the polymerization of two pro-α1 and one pro-α2
chains into the triple helical procollagen molecule. Extracellularly, the globular termini of
procollagen are removed by proteolysis, yielding trimeric collagen monomers of a little
over 300-nm long. Five monomers assemble in a quarter-staggered fashion to form the
microfibril, the basic subunit of the collagen fibril (Figure 1). Specifically, along the fibril’s
long axis exists a repeating D-period pattern of molecular organization. Within the 67-nm
D-period, groups of five neighboring collagen molecules wind around each other into
microfibrils that interdigitate with neighboring microfibrils to form practically inseparable
connections within the fibril. The amino acid sequences of the single collagen molecules
are found within each five-molecule segment that defines each D-period. Because ~300 nm
(collagen triple helix length)/67 nm (D-period length) produces a non-integer number,
the D-period contains a region of incomplete overlap, called the gap zone. This space
within the microfibril plays a role in the biomechanical properties of the fibril. The gap
region also allows biomineralization of bone by accommodating hydroxyapatite crystal
formation and growth [16,17]. Because of the gap zone, the remaining four full-length
segments arrange around each other forming a twist that somewhat mirrors the superhelix
of the collagen molecule, albeit on a larger scale [18]. Each microfibril (Figure 1B,C), and its
neighbors may be connected by N- and C-terminal intermolecular cross-links, yet, collagen
fibrils exhibit varying degrees of crosslinking depending on tissue location, age, and other
circumstances [3]. Other collagen types, proteoglycans (PGs), and matrix macromolecules
typically assemble onto the fibril to impart tissue-specific properties to the polymer [3,19].
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3. Creating a “Road Map” or Interactome of Type I Collagen
Over the past fifty years, a significant amount of information has been discovered
about type I collagen, including its primary sequences, post-translational modifications,
mechanisms of folding and polymerization, identification of its numerous binding partners,
and mutations that result in a spectrum of diseases [1,3,5]. Twenty years ago, one of our
labs began creating a type I collagen interactome in an effort to discover deep insights
into the collagen structure-function relationship [22]. For example, we hoped to clarify
the fundamental issues of whether type I collagen’s structural features, ligand binding
sites, and mutations are distributed randomly or non-randomly on the molecule, and
whether the protein has domains dedicated to specific functions. Furthermore, we wanted
to know if we could correlate the positions of mutations in the collagen molecule and the
disorders they cause, with their effect on protein expression or the disruption of a specific
protein function. As the basis for the interactome, we used a model representing collagen
monomer alignment within the fibril according to complementary electrostatic interactions,
resulting in a molecular overlap of approximately a quarter stagger between the monomers,
and zones of complete (overlap zone) and incomplete (gap zone) overlap [23] (Figure 1).
Thus, on the interactome, the primary sequences of the α1(I) and α2(I) chains of five
collagen molecules are arranged sequentially from the N-terminus to the C-terminus.
The collagen molecule was then annotated with known functional sites such as those
for intermolecular crosslinking, glycosylation, and matrix metalloproteinase-1 (MMP-1)
cleavage. Next, the proposed binding sites for dozens of collagen-binding ligands such
as cytokines, cell adhesion molecules, and proteoglycans were indicated. Finally, the
positions of substitution mutations associated with human diseases including osteogenesis
imperfecta (OI; brittle bone disease), Ehlers Danlos syndrome (EDS; although some EDS
mutations map to type I collagen’s N-terminal region, most map to type III collagen as
discussed later in this review), osteoporosis, and others were included (Figure 2). As
an outcome, our interactome incorporated hundreds of ligand binding sites, functional
domains, and human mutations [6,22].
A qualitative analysis of the collagen interactome revealed several observations. Particularly, ligand binding sites appear not to be randomly distributed as evidenced by at
least three hot spots for ligand binding where many ligands exhibit overlapping, or in
some cases, identical binding sites. On the other hand, some regions of the collagen fibril
exhibit few or no ligand binding sites. Because of their prominence, ligand binding hot
spots were named major ligand binding regions (MLBRs) [6]. Moreover, relatively more
ligand binding sites located to the C-terminal half of the collagen molecule.
Multivalency in the binding of several ligands to collagen seemed to be a theme (e.g.,
for the secreted protein rich in aspartic acid and cysteine, SPARC [24]; discoidin domain receptor 2, DDR2 [25,26]; and integrin binding sites [27,28] as such ligands displayed multiple
binding sites for collagen, each on different monomers of the fibril. Analysis of patterns of
ligand binding sites and mutation distributions revealed the collagen fibril to comprise two
distinct functional domains [22] (Figures 2 and 3). Most of the dynamic aspects of collagen
biology are proposed to occur in one region, called the “cell interaction domain”, which
occupies much of the fibril’s overlap zone. This domain includes sequences mediating the
binding of cell surface integrin receptors (a predominant mechanism of cell-collagen adhesion and interactions), various bioactive factors, collagen scission/remodeling by MMP-1
(vertebrate collagenase), angiogenesis, and hemostasis (blood clotting). The remainder
of the fibril comprises the “matrix interaction domain”, proposed to assume a predominantly structural role, where intermolecular crosslinking between collagen monomers
occurs, and PGs bind to regulate fibril solubility and inter-fibrillar spacing among other
functions [19,29]. Furthermore, the matrix interaction domain likely harbors the putative
sites where biomineralization initiates in tissues like bone. The mechanism of collagen
biomineralization remains elusive; substantial data support three non-mutually exclusive hypotheses. The first maintains that the fibril contains several amino acid sequences
and post-translational modifications that may potentially nucleate hydroxyapatite min-
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eral [9–11,30–36]. Alternatively, several acidic non-collagenous bone phosphoproteins (e.g.,
SIBLING proteins such as osteopontin, bone sialoprotein, and phosphophoryn) are proposed to associate with collagen to provide the mineralization substrate [12,37]. Finally, it
has
been proposed that the spaces within and between the microfibrils may support
biominBioengineering 2021, 8, x FOR PEER
REVIEW
6 of 24
eralization without the need for mineralization nucleation sequences or collagen-associated
proteins [38–41].
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interactome illustrates that OI mutations at the N terminus tend to be milder, and as one
moves toward the C terminus the frequency of lethal mutations increases. In contrast, the
“regional model” suggests that some mutations may directly disrupt specific functions of
the mature protein resulting in disease pathologies [42,44]. Several possible examples of
the latter were revealed by analysis of our collagen interactome. Thus, mutation silent
zones appear on collagen monomer 3 (Figure 2) flanking the preferred binding site for
αlβ1/α2β1 integrin receptors—GFOGER—and implying a critical functional role for this
sequence [22]. Moreover, on the α2(I) chain, clusters of lethal OI mutations alternate with
non-lethal ones, with the former corresponding to zones for the binding of PGs that play a
crucial role in fibril structure and biology [2]. Further, some consecutive runs of glycine
residues associated exclusively with lethal, non-lethal, or no mutations exist throughout
the protein, in no discernable pattern. Many of the non-OI, or “atypical” mutations also do
not exhibit a gradient of phenotype severity but rather, cluster to a few distinct zones on
the fibril [22].
4. Translating the Collagen Interactome into the Three-Dimensional (3D) “Living” Fibril
The two-dimensional (2D) type I collagen interactome cannot distinguish between
surface-exposed accessible sequences capable of interacting with cells and various bioactive
factors, and inaccessible ones located internally within the fibril. Therefore, we will examine
selected interactome data in the context of the X-ray diffraction model of the collagen
microfibril created by one of our research groups. Before doing so, we will introduce the
collagen microfibril structure in the context of the collagen fibril.
The collagen fibril is a crystalline construct, demonstrated by its ability to diffract
X-rays particularly when extracted from a tissue in a hydrated, minimally-strained
state [45–47]. The collagen microfibril model was determined from X-ray diffraction
analysis of rat tendon type I collagen molecules in situ [18]. Fiber diffraction data collected
from native and heavy atom-derivatized rat tail tendons were used to solve the structure
of the collagen molecules via multiple isomorphous replacement [22]. A molecular model
was constructed based on the primary sequences of the three α chains of type I collagen,
and superhelical parameters were determined from structural analyses of triple helical
peptide collagen models [18,48]. The electron density map representing the microfibril has
a resolution of 0.516 nm along the fiber axis and 1.11 nm perpendicular to that. Translating
the positions of functional sites from the collagen interactome to the three-dimensional
microfibril model was accomplished by performing solvent-accessible surface calculations
and rendering using SPOCK [49] with a 0.14 nm default probe size. The functional sites
were color-highlighted within this representation. The nearly identical sequence identity
between rat and human type I collagen justifies localizing functional sequences of human
type I collagen on the rat-based collagen structure.
Thus, to obtain a 3D, more physiologically relevant view of the collagen fibril we projected data from the interactome onto the collagen microfibril X-ray diffraction model [50]
(Figure 4). Significantly, it was discovered that the domain model indicated by analysis
of the interactome also held true for the native fibril. Next, we investigated surfaceaccessible and inaccessible regions of the fibril and their associated binding sites. Thus,
surface accessibility of about a dozen functional sites was qualitatively ranked according to a four-tiered scale ranging from high, moderate, low, to least accessible to water
molecules and small ions. For binding of ligands to the collagen fibrils, we identified some
unobstructed sites, including glycoprotein VI (GPVI) [51], Endo180 (sequence required
for endocytic recycling of collagen) [52,53], osteoclast-associated receptor (OSCAR; not
shown on collagen interactome) [54], P986 (3-prolyl hydroxylation at amino acid position
986 required for collagen folding and post-translational modifications) [55], fibrillogenesis
control sequences [56], residues mediating intermolecular crosslinking [3], and binding
sites for cartilage oligomeric matrix protein (COMP) [57] and pigment epithelium-derived
growth factor (PEDF) [58], which appear to co-locate at the interface of (GPO)5 at the
C-terminal end of the triple helix and the start of the non-helical C-telopeptide [21,59].
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revealed that the C-terminal portion of collagen is located at the apex of the fibril’s ridges,
making it the exposed part of collagen, and thus freely accessible to cells and macromolecules [50]. Notably, the collagen sequences comprising the recessed portions or valleys
of the fibril surface carry out structural duties, including sites for the binding of the

Bioengineering 2021, 8, 3

10 of 23

decorin core protein [60], and in providing possible sites to nucleate and/or accommodate
hydroxyapatite mineral growth in skeletal tissues. Thus, the exterior of the native collagen fibril projects a robust, structural face to the environment, yet is poised to promote
hemostasis in response to tissue injury.
Conditional Cell and Matrix Interaction Domains of the Type I Collagen Fibril
That these findings support a relatively stable, structural role for the collagen fibril
is not surprising, but how can that view be reconciled with the abundant data in the
literature showing collagen to be a dynamic substrate for cell-matrix adhesion, activation,
and differentiation? The answer may come from collaborative studies by several of our
labs, that analyzed the mechanism of collagen remodeling by MMP-1 [21,50,61,62] and
determined that for collagen remodeling to occur, the fibril must be essentially “opened up”
to render the MMP-1 cleavage site available for scission by the enzyme. For this to happen,
the C-terminal telopeptide must first either be proteolytically removed by MMP-1 or
another enzyme (e.g., telopeptidase), and/or pushed aside to expose the MMP-1 cleavage
site on monomer 4 by either local mechanical action at the site on one or more molecules or
via a larger tonal scale strain on the fibril/tissue [47]. Once monomer 4 is cleaved by MMP-1,
other monomers with their host of binding sites, such as monomer 3 containing GFOGER,
monomer 2 containing the Von Willebrand’s Factor (vWF), SPARC, and DDR2 binding
sites become available to cells and bioactive factors. The domain model of the collagen
fibril, when viewed through this lens, suggests that the cell and matrix interaction domains
may be conditionally and mutually exclusively available according to the physiological
state of the tissue in which the fibril resides, in a cyclic process (Figure 5). Thus, in a stable
tissue, the static fibril will be dominated by structural functions of the matrix interaction
domain. Tissue injury causes bleeding into the collagenous stroma, triggering the onset
of the dynamic fibril where the functions of the cell interaction domain take over. Platelet
adhesion to collagen via GPVI-(GPO)5 and possibly integrin receptor-GASGER ligations
occur, leading to platelet aggregation, activation, and hemostasis. Release of MMP-1 from
activated platelets and/or inflammatory cells causes telopeptide removal (or relocation)
to expose sites for MMP-1 cleavage of collagen, and bioactive sites of the collagen fibril
which are functionally crucial in the subsequent events. Moreover, as the fibril is further
denatured and degraded, cryptic epitopes such as the pro-angiogenic sequence RGDKGE
may be exposed [63], and bioactive collagen peptides [64,65] may be released into the
tissue milieux which also promote the tissue regeneration cascade. Inflammatory cells
are activated, enter the tissue, and migrate on the collagenous stroma in response to
chemotactic factors and cytokines released by the activated platelets. The damaged tissue
is removed by inflammatory cells, and tissue cells migrate and proliferate into the site of
injury, while producing a new collagen-rich ECM which in turn promotes terminal tissue
differentiation [14]. Integration and crosslinking of the newly synthesized collagen into a
mature ECM culminates in re-emergence of the quiescent tissue state and the static fibril.
For circumstances aside from tissue injury, such as bone remodeling or tissue growth,
secretion of MMP-1 by cells such as osteoclasts or fibroblasts is also assumed to trigger
collagen remodeling and initiation of the subsequent static to dynamic fibril cycle. Other
possible mechanisms may also trigger the cycle such as cell-assisted mechanical relocation
of the C-terminal telopeptide.
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lizing [75,76], we used the collagen stability calculator [77] to plot the stability of the type
III collagen molecule along its length according to its amino acid triple composition. We
observed that in three locations on the type III collagen fibril, atypical amino acid triplets
co-localized, predicting three major regions of decreased stability. We thus proposed a
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6.1. Anti-Collagen Antibodies
6.1. Anti-Collagen Antibodies
In the context of fibril-ligand interactions, the C-terminal telopeptide region contains
In the context of fibril-ligand interactions, the C-terminal telopeptide region contains
some of the most significant interaction sites [22,61,62]. As stated above, this is partly due
some of the most significant interaction sites [22,61,62]. As stated above, this is partly due
to its occupying the “up” ridge of the pleated gap-overlap D-periodic structure, with the
to its occupying the “up” ridge of the pleated gap-overlap D-periodic structure, with the
C-terminal telopeptide jutting out into the milieu (Figures 1 and 4). It is also because the
C-terminal telopeptide jutting out into the milieu (Figures 1 and 4). It is also because the
radial organization of the microfibril leaves the C-terminal telopeptides on the outside of
radial organization of the microfibril leaves the C-terminal telopeptides on the outside of
the fibril [62]. Thus, this region appears available to interact with immunoglobulins and
the fibril [62]. Thus, this region appears available to interact with immunoglobulins and
immunoglobulin-like receptors which may play prominent roles in matrix remodeling and
immunoglobulin-like receptors which may play prominent roles in matrix remodeling
antigen recognition [54,59]. The presence of these interaction sites “makes the C-terminal
and antigen recognition [54,78]. The presence of these interaction sites “makes the C-terarea of the mature collagen fibril an important region for receptor-mediated activation of
minal area of the mature collagen fibril an important region for receptor-mediated activacells, inflammation, cellular recruitment, and prevention of apoptosis” [59].
tion Recent
of cells,studies
inflammation,
cellular recruitment,
and collagen
prevention
ofthat
apoptosis”
[78].
raised antibodies
against human
[78],
were later
shown
Recent
studies
raised
antibodies
against
human
collagen
[79],
that
were
later
shown
to bind the (GPO)5 sequence located at the junction of the triple helix and C-terminus,
to bind the
(GPO)
5 sequence located at the junction of the triple helix and C-terminus,
revealing
novel
immunologically
relevant properties at the gap-overlap interface [59]. The
revealing
novel
immunologically
properties
at the gap-overlap
interface
[78]. The
binding brought the antibody intorelevant
the range
of the tyrosine
residues found
exclusively
binding
brought
the
antibody
into
the
range
of
the
tyrosine
residues
found
exclusively
within the telopeptides. This is significant due to the importance of tyrosine to the function
within
the an
telopeptides.
This is significant
duereceptor
to the importance
of tyrosine
to the
funcof
OSCAR,
immunoglobulin-like
activating
of the leukocyte
complex
[54,79].
tion
of
OSCAR,
an
immunoglobulin-like
activating
receptor
of
the
leukocyte
complex
This receptor is expressed at high levels in osteoclasts. When bound to collagen, OSCAR
[54,80]. several
This receptor
is expressed
high levels
osteoclasts.ofWhen
bound
to collagen,
triggers
signaling
pathways at
involved
in theinmodulation
matrix
remodeling
and
OSCAR
triggers
several
signaling
pathways
involved
in
the
modulation
of
matrix
remodimmune cell behaviors. Similar to the anti-(GPO)5 antibody, modeling of OSCAR binding
eling
and immune
cell behaviors.
the binding
anti-(GPO)
to
collagen
demonstrated
preferenceSimilar
for the to
same
site.5 antibody, modeling of OSCAR binding to collagen demonstrated preference for the same binding site.
6.2. Collagen Fibrillogenesis as a Potential Anti-Fibrotic Target
Knowing specific roles of collagen molecules and fibrils allows their targeting to
achieve therapeutic effects. For example, one of our research groups targeted collagen
fibrillogenesis to block the growth of fibril-rich scars formed in response to injury [80,81].
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While fibrillogenesis is a crucial element of the mechanism that maintains physiological
homeostasis of connective tissues, excessive collagen biosynthesis, and accelerated fibril
formation define fibrotic diseases. Regardless of the etiology and tissue-specific pathways
of these diseases, it is collagen-rich fibrillar deposits that disrupt vital functions of fibrotic
tissues and organs. For instance, in pulmonary fibrosis, dense collagen-rich tissue obstructs
the exchange of gases, thereby limiting blood oxygenation [82]. Moreover, excessive
formation of collagen-rich scars in the skin, peripheral nerves, vocal cords, cornea, and
other tissues severely limits their vital functions [83–86].
Currently, there are no therapeutics available that reduce fibrosis effectively and
safely. The main targets that may limit the fibrotic response to tissue injury include profibrotic inflammation and activation of pro-fibrotic cells. These targets are nonspecific
intracellular processes that control not only the accelerated production of elements of the
scar tissue, most notably collagen, but also other processes not associated with fibrosis. In
an attempt to target fibrosis specifically and safely, one of our research groups identified
collagen fibrillogenesis as an attractive anti-fibrotic target [80]. The rationale for selecting
fibrillogenesis was that, regardless of the type of injury or its anatomical location, collagen
fibrils are the main element of the fibrotic tissue formed due to excessive scarring. This
notion is illustrated by the fact that collagenous fibrils comprise over ninety-five percent
of the dry mass of pulmonary scars [87]. To attack fibrillogenesis therapeutically, our
group selected collagen telopeptides as the ultimate target. As demonstrated by various
studies, telopeptides drive the collagen-collagen binding interaction that plays a crucial
role in the nucleation and growth of the fibril [56,88]. Thus, blocking telopeptide-mediated
interactions inhibits collagen fibril formation in a concentration-dependent manner [80,89].
Subsequently, utilizing a de novo fibril formation experimental system, we showed that
a monoclonal antibody targeting an epitope within the C-terminal telopeptide of the
α2(I) chain—its C-terminal telopeptide (α2Ct)—inhibits fibril formation in vitro and in
an organotypic model of skin fibrosis [80,89]. These observations strongly suggested
that blocking type I collagen fibrillogenesis may reduce the formation of fibrotic tissues
in vivo. More recently, we confirmed the anti-fibrotic effects of the anti-α2Ct monoclonal
antibody in vivo [80,81]. Moreover, we demonstrated that the anti-α2Ct antibody binds
both free, intact type I procollagen and type I collagen molecules [80]. Consequently,
this antibody inhibits the nucleation step in fibril formation by blocking the assembly
of collagen monomers. Its interaction with mature fibrils, however, is less understood.
One study that utilized type I collagen fibrils formed de novo demonstrated, however,
that the antibody interacted with the gap region of the type I collagen fibril [89]. Since
these fibrils were formed in vitro and contained type I collagen only, there were no other
macromolecules present that could block the access to the gap region in the fibrils, making
the in vivo relevance of these data unclear.
In the context of its anti-fibrotic application, determining potential mechanisms of
the anti-α2Ct antibody’s binding interactions with the collagen fibrils is crucial because:
(i) binding of the antibody to growing, immature fibrils would inhibit their further growth,
and (ii) binding of the antibody to the mature fibrils could reduce its bioavailability. Thus,
we carried out molecular binding simulations between the α2Ct antibody and C-terminus
of type I collagen as detailed below.
6.3. Modeling of Anti-α2Ct Antibody-Collagen Fibril Interactions
6.3.1. Collagen C-Terminus
To illustrate the possible interaction between the anti-α2Ct antibody and the
C-terminus of human type I collagen, we employed the rat tendon X-ray diffraction model
of the type I collagen fibril published by one of our groups [18]; however the predicted
epitope, or sequence for the binding of the antibody to the α2Ct of the rat protein is not
a perfect match with that of the human protein against which the antibody was raised
(Table 1). The sequences are reasonably homologous between rat, human, and other vertebrates commonly used in research (Table 1); however, the α2Ct epitope of the human

perfect match with that of the human protein against which the antibody was raised
(Table 1). The sequences are reasonably homologous between rat, human, and other vertebrates commonly used in research (Table 1); however, the α2Ct epitope of the human
protein GGGYDFGYDGDFYRA, appears to be truncated in the X-ray diffraction model of
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the rat protein to: xGGYDF (where x is either G or S). The epitope is however clearly located at the exterior of the collagen fibril in the highly exposed C-terminus as expected.
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6.4. A Broad View on Blocking Matrix Assembly as an Anti-Fibrotic Therapy
The model we propose for the anti-α2Ct antibody-collagen fibril interaction would
provide a blue print for other interactions with anti-fibrotic potential. We realize that
although type I collagen is the main component of fibrotic deposits, other collagenous and
non-collagenous macromolecules also contribute to the fibrotic mass. For instance, the
production of fibronectin is also upregulated in fibrotic processes, and its assembly may
precede that of collagen fibrils. Consequently, a peptide inhibitor of fibronectin fibrillogenesis has been shown to exhibit anti-fibrotic properties [90]. Other compounds were also
suggested as inhibitors of collagen fibrillogenesis, and potentially, anti-fibrotic therapeutics.
In one example, researchers employed α-lipoic acid to block a site-specific interaction that
drives collagen fibril assembly [91]. In similar experiments, trigonelline hydrochloride
was shown to be an effective inhibitor of collagen fibrillogenesis [92]. Recently, two small
molecules, nintedanib, and pirfenidone, were approved for the treatment of idiopathic
pulmonary fibrosis (IPF). Although their mechanism of action is not clearly established,
nintedanib is a receptor kinase inhibitor of platelet-derived growth factor receptor and
vascular endothelial growth factor receptor, all of which play roles in the pathology of
IPF. Pirfenidone is an anti-fibrotic, anti-inflammatory, and antioxidant compound with
beneficial effects in organ fibrosis, but its direct targets are not known. In addition to the
cellular effect of these compounds, however, it was demonstrated that they directly block
collagen fibril formation [93]. Furthermore, since type I collagen molecules copolymerize
with type III and type V collagens to form heterotypic fibrils in vivo, we cannot exclude the
possibility that the anti-αCt antibody disrupts the co-assembly process [94,95]. These examples further justify targeting the assembly of collagen-rich matrices as potential anti-fibrotic
therapies.
7. Collagen-Induced Angiogenesis
In adult mammals, angiogenesis—or new capillary growth from an existing
vasculature—is the single mechanism by which new blood vessels develop [96]. Angiogenesis is involved in homeostasis and diseases, including for example, solid tumor
growth and metastasis, rheumatoid arthritis, hemangioma formation, and diabetic retinopathy [96]. It is a complex process by which endothelial cells degrade the surrounding ECM,
migrate, proliferate, and differentiate to form new vessels [97]. Angiogenesis depends
upon the interaction of endothelial cells with the ECM via cell surface adhesion molecules
including the integrins, and the activities of growth factors and cytokines [98]. Because
type I collagen is a ubiquitous component of many tissues that undergo angiogenesis
during embryogenesis, it may play a role in promoting normal as well as pathological
angiogenesis. For example, in vivo, angiogenesis is disrupted in the chick embryo by inhibiting collagen triple helix formation or fibrillogenesis, using several chemical inhibitors
of those processes. In fact, type I collagen has also been demonstrated to be among the few
optimal scaffolds for the induction of angiogenesis in vitro. Thus, type I collagen synthesis
by endothelial cells [99,100] precedes angiogenesis, and is limited to the vicinity of capillary
tube formation in cultures [101,102]. Furthermore, endothelial cells grown between or
within collagen gels rapidly form capillary tube networks [103,104].
Integrin Receptor Ligation and Clustering in Collagen-Induced Angiogenesis
Our research showed that in vitro, apical type I collagen gels rapidly induce angiogenesis in human endothelial cell monolayers (Figure 9) [105]. Further, angiogenesis required
the engagement between the α2β1 integrins of the endothelial cells and the central integrin
binding site, GFOGER, on the collagen molecule [105]. Further studies demonstrated that
in quiescent endothelial cell confluent monolayers, in the absence of exogenous collagen,
the α2β1 integrins concentrated along cell-cell borders. After adding apical collagen gels to
the cultures, the integrins redistributed to apical cell surfaces, aligning with collagen fibers,
which also relocated during angiogenesis [106]. Based on these observations, as well as
on the distribution of integrin binding sites in the type I collagen fibril, we proposed that
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8. Bioengineering Applications: Angiogenic Polymers
We previously reviewed strategies to produce angiogenic polymers based on our
understanding at that time of the collagen structure-function relationship and mechanisms
of angiogenesis [7]. Here we will update and expand upon some of those strategies accounting for the newer information on these topics. As pointed out previously, type I collagen
from animal sources is an effective angiogenic polymer. Moreover, collagen is easy to
isolate in the lab but is also commercially available at reasonable cost. The collagen preparations we used to promote angiogenesis consisted of acid soluble, non-pepsinized, type I
collagen from rat tail tendon that were applied to endothelial cells as gels. The angiogenic
properties of collagen required its native, triple helical, and fibrillar conformations [105].
According to the domain model of collagen fibril function, for a collagen fibril to support
angiogenesis, it must have an accessible MMP-1 cleavage site, which must be cleaved by
MMP-1 released by endothelial cells to expose the underlying central integrin binding
site, GFOGER. Indeed it has been reported that growth factor-dependent angiogenesis
in vivo requires MMP-1-mediated cleavage of collagen [107]. Collagen preparations of the
type we used are expected to have most of their telopeptides, with a relatively low density
of intermolecular crosslinking at those regions which should facilitate their removal by
MMP-1. Such non-pepsinized, telopeptide-containing collagen is preferred as an angiogenic polymer since the presence of telopeptides allows for rapid fibrillogenesis and robust
gel formation in comparison with atelopeptidic collagen produced through pepsinization,
because the latter may not undergo fibrillogenesis or gelation adequately [3].
8.1. Recombinant Super-Angiogenic Collagens
To engineer a super-angiogenic polymer, one may consider creating recombinant
collagens with an enhanced capacity to ligate and cluster endothelial cell integrin receptors.
The most obvious way to do so would be to add integrin binding sequences to surfaceexposed regions of the fibril; based on our structural mapping, those could be placed within
monomer 5 and the gap zone portion of monomer 4. Given the diameter of the integrin
heterodimer of about 10–20 nm, only two or three such receptors could simultaneously
ligate the fibril and be accommodated within the 67 nm D-period. Since there is only one
low affinity integrin binding site on the fibril surface—GASGER, that sequence should be
replaced by the high affinity integrin binding sequence GFOGER. Possibly, up to two other
GFOGER sequences might be inserted elsewhere in the exposed fibril regions, taking care
not to disrupt other functional sites or residues crucial for fibril assembly and integrity
(see Figures 2 and 4). Other type I collagen sequences that should not be removed or
altered in the recombinant protein include those proposed necessary for the angiogenic
properties of collagen: the MMP-1 interaction domain; the MMP-1 cleavage sequence; the
central integrin binding site GFOGER; and the N- and C-terminal heparin binding sites.
Functional sites that may be removed or modified to render them inactive include those
for the binding of SPARC, PEDF, and decorin, all of which may exhibit anti-angiogenic
activities [108–111]. Including C- and N-telopeptides in the polymer would be advantageous for rapid fibrillogenesis and robust gel formation properties of the material, but
removing the capacity for intermolecular crosslinking within the C-terminal telopeptide is
suggested, to render the polymer more easily proteolyzed by MMP-1, a proposed step in
angiogenesis induction by collagen.
8.2. Collagen Mimetics as Angiogenesis Substrates
The discovery and application of collagen mimetics is an emerging field in biotechnology, and is reviewed extensively by Xu and Kirchner in this issue. The “bare bones”
of the collagen fibril vis-a-vis its angiogenesis promoting activity appears to be its ability
to ligate, and by virtue of its multivalency, cluster α2β1 integrin receptors. Theoretically,
several classes of novel materials may mimic that activity and substitute for collagen. One
class comprises two versions of synthetic “sticky-ended” collagen-like peptides that selfassemble into triple helices and higher ordered structures resembling collagen fibrils, and
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in one case also forms stable hydrogels [112,113]. The peptides can carry the high affinity
integrin binding site GFOGER crucial for angiogenesis promotion, as well as the sequence
of type I collagen rendering the polymers sensitive to MMP-1 degradation; the latter would
ensure its shorter in vivo half-life if desired. Such peptides could also be modified to
promote hemostasis instead, by carrying GPO5 , and in some cases, also GFOGER if both
hemostatic and pro-angiogenic activities are desired. A second class of collagen mimics is
suggested by our in vitro angiogenesis studies [106]. Thus, biodegradable beads (e.g., albumin, polycaprolactone, or poly(D,L-lactide-coglycolide) among others) of about 1–5 µm
diameters and onto which anti-α2β1 integrin antibodies are adsorbed or covalently linked
may also mimic the angiogenic activities of collagen. Instead, it may be of interest to affix
anti-α2β1 integrin antibodies at high densities on biodegradable fibrous polymer filaments
to achieve a more collagen-like substrate for angiogenesis. The angiogenic collagen mimics
described here may in several respects be preferable to using native or recombinant collagen as angiogenic substrates to avoid the drawbacks of using large, complex proteins from
natural sources, including the presence of undesirable binding activities, batch-to-batch
variations, and potential immunogenicity, among other considerations.
9. Summary
Here we attempted to reconcile the biology of the type I collagen fibril with its
complex three-dimensional structure. Data suggest that in quiescent tissues, the fibril
assumes structural duties, but tissue trauma may lead to collagen proteolysis, exposing a
host of cell- and ligand-binding sites crucial for tissue regeneration. Moreover, our research
helped identify a possible mechanism of action of an anti-fibrotic collagen-binding antibody,
and develop non-collagenous agents that mimic collagen’s ability to cluster endothelial
integrins and promote angiogenesis. Further structure-function analysis of collagen fibrils
in various physiologic contexts will help elucidate poorly-understood aspects of collagen
biology like fibril assembly and biomineralization, and facilitate the discovery of novel
therapies to combat human pathologies where collagen plays prominent roles.
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